Bone health study of a long-acting factor VIII for hemophilia A
Part of Blood & lymphatic clinical trials.
This study tests whether a long-acting factor VIII medicine (rFVIIIFc) helps protect the bones and joints of people with hemophilia A. If you have severe or moderate hemophilia with joint damage and are already on this treatment, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe hemophilia A, or moderate hemophilia A with joint damage from bleeds
- You are currently taking a long-acting factor VIII drug (rFVIIIFc) to prevent bleeds
- You have been on a regular (standard) factor VIII treatment for at least one year in the past
- You are willing to have tests on your bones and joints (like X-rays or scans)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study looks at how two different hemophilia A treatments affect bone health over time. It tests if one medicine is better at keeping bones strong than the other.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
This study tests a preventive treatment called efanesoctocog alfa to see if it can help people with moderate to severe hemophilia A who have joint swelling (synovial hypertrophy). It aims to reduce joint bleeding and improve joint health.
This study tests a new medicine called KN057 for people with hemophilia A or B, with or without inhibitors, to see if it helps prevent bleeding. It is for people who still have frequent bleeding episodes despite current treatments.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
Hear when a new Severe Hemophilia A Without Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.